Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Free Report) – Equities research analysts at Zacks Research upped their FY2026 earnings per share (EPS) estimates for shares of Reviva Pharmaceuticals in a report issued on Wednesday, May 27th. Zacks Research analyst J. Vandermosten now forecasts that the company will earn ($1.96) per share for the year, up from their prior forecast of ($2.21). The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($2.96) per share. Zacks Research also issued estimates for Reviva Pharmaceuticals’ FY2027 earnings at ($1.44) EPS.
Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10).
Check Out Our Latest Report on RVPH
Reviva Pharmaceuticals Stock Up 13.1%
NASDAQ RVPH opened at $0.43 on Friday. The stock has a market cap of $5.68 million, a PE ratio of -0.11 and a beta of 0.75. Reviva Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $23.00. The business has a 50 day moving average price of $0.74 and a two-hundred day moving average price of $5.16.
Hedge Funds Weigh In On Reviva Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in RVPH. Geode Capital Management LLC lifted its stake in Reviva Pharmaceuticals by 87.6% during the fourth quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock worth $293,000 after purchasing an additional 489,711 shares during the last quarter. Millennium Management LLC lifted its stake in Reviva Pharmaceuticals by 15.0% during the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after purchasing an additional 223,178 shares during the last quarter. Armistice Capital LLC bought a new position in Reviva Pharmaceuticals during the second quarter worth $1,026,000. XTX Topco Ltd lifted its stake in Reviva Pharmaceuticals by 63.6% during the fourth quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock worth $46,000 after purchasing an additional 63,893 shares during the last quarter. Finally, State Street Corp lifted its stake in Reviva Pharmaceuticals by 202.4% during the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after purchasing an additional 256,500 shares during the last quarter. 63.18% of the stock is currently owned by hedge funds and other institutional investors.
About Reviva Pharmaceuticals
Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.
The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.
See Also
- Five stocks we like better than Reviva Pharmaceuticals
- Wall Street Is Starting to Talk About Tesla’s Endgame
- Meta’s Manus Mess: Why China Blocked the Deal and What It Means
- China Deal Ignites Boeing’s Financial Afterburners
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
